Pharmaceutical Investing RAMM Pharma Announces Approval and Registration of Epifractán™ 2 Percent by Peru’s Ministry of Health
Pharmaceutical Investing RAMM Pharma Announces Approval and Registration of Epifractán™ 5 Percent by Peru’s Ministry of Health and Enters Distribution Agreement to Supply Pharmacies in Peru
Cannabis Investing RAMM Pharma Corp. Announces Postponement of Filing of Interim Financial Statements
Cannabis Investing RAMM Pharma Corp. Receives Federal Approval and Registration of XALEX™ 10 (cannabidiol) Oral Solution
Pharmaceutical Investing RAMM Pharma Corp. Provides Details on Operational Activities to Support COVID-19 Medical Response Effort & Corporate Update
Cannabis Investing RAMM Pharma Corp. to Acquire NettaLife, a Leading Developer of Cannabis-Based Products for Pets and Large Animals
Cannabis Investing RAMM Pharma Corp. (formerly MTC Growth Fund-I Inc.) Announces Closing of Business Combination with RAMM Pharma Holdings Corp., Medic Plast S.A. and Yurelan S.A.; Trading Anticipated to Commence November 8, 2019
Cannabis Investing RAMM Pharma and MTC Announce Receipt of Conditional Approval to List on the CSE and Provide an Update on Transaction Status
Group Eleven Intersects 7.5m of 20.1% Zn+Pb and 51 g/t Ag, incl. 2.2m of 37.5% Zn+Pb and 72 g/t Ag at Ballywire in Step-Out Drilling; Upcoming Drilling at Cu-Ag Target and 'D' Gravity Anomaly
